Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 39Active not recruiting 19Terminated 2Completed 2Withdrawn 1Suspended 1Not yet recruiting 1Enrolling by invitation 1Available 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 6Breast Neoplasms 5Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Glioma 3Solid Tumors 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Melanoma 2Brain Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Papillomavirus Infections 1Pancreatic Ductal Adenocarcinoma 1PTEN Gene Mutation 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neuroma 1

Interventions

olaparib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Urinary Bladder Neoplasms × 30 days × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡